FDA approves new CV indication for Jardiance

The US Food and Drug Administration on Friday approved a new indication for Jardiance (empagliflozin) to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and cardiovascular disease.

The drug is marketed by US pharma major Eli Lilly (NYSE: LLY), whose shares increased 3% to $68 in heavy late trading on Friday afternoon, and German family-owned Boehringer Ingelheim.

Under their diabetes collaboration, Lilly and Boehringer co-market several drugs across 17 countries, sharing costs and revenues. Lilly records revenue from Jardiance, which totaled just over $125 million in the first nine months of this year, under collaboration and other revenues in its financial reports.